Caribou stockholders elect Guggenhime, Johnson, Whiting as Class II directors and ratify Deloitte as auditor

Caribou Biosciences, Inc.

Andrew Guggenhime: 31.0M votes for, 5.3M withheld, 9.4M broker non-votes.
David L. Johnson: 31.8M for, 4.5M withheld, 9.4M broker non-votes.
Nancy Whiting: 31.9M for, 4.5M withheld, 9.4M broker non-votes.
Ratification of Deloitte & Touche as independent auditor: 45.7M for, 51.8K against, 82.4K abstain.
Annual meeting held June 15, 2023; all proposals passed.

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Caribou Biosciences, Inc. shareholders approved Ratification of Selection of Independent Registered Public Accounting Firm at the 2023-06-15 meeting.

Proposal: auditor ratification
Outcome: passed
Meeting: 2023-06-15

Exact text from the filing

Proposal 2 - Ratification of Selection of Independent Registered Public Accounting Firm The stockholders ratified the selection by the Audit Committee of the Company’s Board of Directors of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023, by the following votes: Votes For Votes Against Votes Abstain 45,652,597 51,771 82,435

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Caribou Biosciences, Inc. shareholders approved Election of Two Class I Directors at the 2023-06-15 meeting.

Proposal: director election
Outcome: passed
Meeting: 2023-06-15

Exact text from the filing

Proposal 1 - Election of Two Class I Directors Each of the following nominees was elected to serve as a Class II director, to hold office until the Company’s 2026 annual meeting of stockholders and until their respective successor is duly elected and qualified or until their earlier death, resignation, or removal. Nominee Votes For Votes Withheld Broker Non-Votes Andrew Guggenhime, M.B.A. 31,032,443 5,325,715 9,428,645 David L. Johnson, M.B.A. 31,840,467 4,517,691 9,428,645 Nancy Whiting, Pharm.D. 31,863,074 4,495,084 9,428,645

View on SEC.gov

Browse all shareholder votes →

Caribou Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001619856-23-000076

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.